Mednet Logo

Do you test your esophageal and gastric specimens for HER2 using IHC, FISH, or both?

What other molecular tests do you routinely order on such tumors?
Community PollStarted

What is your approach to biomarker testing on gastric/esophageal tumors?

56 physicians have voted

Join Mednetto vote and see how they answered.

5 Answers
Mednet Member
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute
Answered on

We ask for IHC and reflex FISH for IHC score of 2. I find it most helpful and efficient when at least HER2, PD-L1, MMR are already done when patients come for medical oncology visits. When patients have advanced, unresectable disease, we have been requesting an expanded molecular panel that includes...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on · Updated on

Per ASCO and College of American Pathology guidelines, we start with IHC. For tumors that are IHC 0/1+ (negative) or 3+ (positive), no further testing is indicated. For IHC 2+ tumors, we then proceed to FISH. IHC 2+ and FISH +ve tumors and IHC 3+ tumors are offered trastuzumab in the metastatic sett...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington Medical Center
Answered on

Our typical approach is to do Her2 IHC and FISH in all new esophageal/gastric adenocarcinoma cases. We also routinely test PDL1 (by CPS), MSI, and TMB. Most patients will also have tumor sent for genomic profiling. In that context, Her2 mutations and ERBB2 will usually be assessed, but our initial d...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on

With the advances in HER-2 directed therapies and availability of novel antibody drug conjugates (ADC), numerous issues are emerging that need to be addressed to optimize the HER-2 testing beyond what we have today. Assessment of low HER-2 expression now has become an important issue. The definition...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · NYU Winthrop Hospital
Answered on

Both IHC and FISH

Join for free or sign in to see the full answer